Luteolin and triptolide: Potential therapeutic compounds for post-stroke depression via protein STAT

Why are you working on the secondary problem of depression when the correct solution is to address the primary problem of 100% recovery? 100% recovery and there is no depression to fix!

 Luteolin and triptolide: Potential therapeutic compounds for
post-stroke depression via protein STAT

Heliyon 9 (2023) e18622
Available online 3 August 2023
2405-8440/© 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Luteolin and triptolide: Potential therapeutic compounds for
post-stroke depression via protein STAT
Tianyang Zhao a, Siqi Sun a, Yueyue Gao a, Yuting Rong a, Hanwenchen Wang b,
Sihua Qi a,*, Yan Li a,**
a Department of Anesthesiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
b The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
A R T I C L E I N F O
Keywords:
Post-stroke depression (PSD)
Text mining
Network
DeepPurpose
GO function
Compound

ABSTRACT

Post stroke depression (PSD) is a common neuropsychiatric complication following stroke closely associated with the immune system. The development of medications for PSD remains to be a considerable challenge due to the unclear mechanism of PSD. Multiple researches agree that the functions of gene ontology (GO) are efficient for the investigation of disease mechanisms, and DeepPurpose (DP) is extremely valuable for the mining of new drugs. However, GO terms and DP have not yet been applied to explore the pathogenesis and drug treatment of PSD. This study aimed to interpret the mechanism of PSD and discover important drug candidates targeting risk proteins, based on immune-related risk GO functions and informatics algorithms. According to the risk genes of PSD, we identified 335 immune-related risk GO functions and 37 compounds. Based on the construction of the GO function network, we found that STAT protein may be a pivot protein in underlying the mechanism of PSD. Additionally, we also established networks of Protein-Protein Interaction as well as Gene-GO function to facilitate the evaluation of key genes. Based on DP, a total of 37 candidate compounds targeting 7 key proteins were identified with a potential for the therapy of PSD. Furthermore, we noted that the mechanisms by which luteolin and triptolide acting on STAT-related GO function might involve three crucial pathways, including specifically hsa04010 (MAPK signaling pathway), hsa04151 (PI3K-Akt signaling pathway) and hsa04060 (Cytokine-cytokine receptor interaction). Thus, this study provided fresh and powerful information for the mechanism and therapeutic strategies of PSD.